GB2463928A - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- GB2463928A GB2463928A GB0817656A GB0817656A GB2463928A GB 2463928 A GB2463928 A GB 2463928A GB 0817656 A GB0817656 A GB 0817656A GB 0817656 A GB0817656 A GB 0817656A GB 2463928 A GB2463928 A GB 2463928A
- Authority
- GB
- United Kingdom
- Prior art keywords
- weight
- component
- composition
- test
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 168
- 239000004094 surface-active agent Substances 0.000 claims abstract description 44
- 125000001453 quaternary ammonium group Chemical group 0.000 claims abstract description 20
- DZCAZXAJPZCSCU-UHFFFAOYSA-K sodium nitrilotriacetate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CC([O-])=O DZCAZXAJPZCSCU-UHFFFAOYSA-K 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000002738 chelating agent Substances 0.000 claims abstract description 12
- 239000002280 amphoteric surfactant Substances 0.000 claims abstract description 8
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 8
- 230000003115 biocidal effect Effects 0.000 claims description 45
- 241000193163 Clostridioides difficile Species 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 12
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000002147 killing effect Effects 0.000 claims description 10
- 241000193403 Clostridium Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 230000003405 preventing effect Effects 0.000 claims description 8
- 150000003841 chloride salts Chemical class 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000004599 antimicrobial Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241000194033 Enterococcus Species 0.000 claims description 4
- -1 alkyiphenols Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- URDCARMUOSMFFI-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(2-hydroxyethyl)amino]acetic acid Chemical compound OCCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O URDCARMUOSMFFI-UHFFFAOYSA-N 0.000 claims description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 241000187495 Mycobacterium terrae Species 0.000 claims description 3
- JYXGIOKAKDAARW-UHFFFAOYSA-N N-(2-hydroxyethyl)iminodiacetic acid Chemical compound OCCN(CC(O)=O)CC(O)=O JYXGIOKAKDAARW-UHFFFAOYSA-N 0.000 claims description 3
- 241001263478 Norovirus Species 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- 241000186367 Mycobacterium avium Species 0.000 claims description 2
- 241000186366 Mycobacterium bovis Species 0.000 claims description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 150000002462 imidazolines Chemical class 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229940048195 n-(hydroxyethyl)ethylenediaminetriacetic acid Drugs 0.000 claims description 2
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 119
- 239000000460 chlorine Substances 0.000 description 63
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 48
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 42
- 229910052801 chlorine Inorganic materials 0.000 description 42
- 239000002689 soil Substances 0.000 description 31
- 230000009467 reduction Effects 0.000 description 29
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 24
- 238000004140 cleaning Methods 0.000 description 16
- 238000010790 dilution Methods 0.000 description 15
- 239000012895 dilution Substances 0.000 description 15
- 108010088751 Albumins Proteins 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 239000005708 Sodium hypochlorite Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000007844 bleaching agent Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 238000010998 test method Methods 0.000 description 12
- 239000000645 desinfectant Substances 0.000 description 11
- MSFGZHUJTJBYFA-UHFFFAOYSA-M sodium dichloroisocyanurate Chemical compound [Na+].ClN1C(=O)[N-]C(=O)N(Cl)C1=O MSFGZHUJTJBYFA-UHFFFAOYSA-M 0.000 description 11
- 230000003330 sporicidal effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 9
- 241001494479 Pecora Species 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- UHXQPQCJDDSMCB-UHFFFAOYSA-L disodium;3-[[9,10-dioxo-4-(2,4,6-trimethyl-3-sulfonatoanilino)anthracen-1-yl]amino]-2,4,6-trimethylbenzenesulfonate Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=C(C)C=C(C)C(S([O-])(=O)=O)=C1C UHXQPQCJDDSMCB-UHFFFAOYSA-L 0.000 description 6
- 239000008233 hard water Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002452 interceptive effect Effects 0.000 description 5
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 241000714201 Feline calicivirus Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PQHYOGIRXOKOEJ-UHFFFAOYSA-N 2-(1,2-dicarboxyethylamino)butanedioic acid Chemical compound OC(=O)CC(C(O)=O)NC(C(O)=O)CC(O)=O PQHYOGIRXOKOEJ-UHFFFAOYSA-N 0.000 description 2
- CIEZZGWIJBXOTE-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]propanoic acid Chemical compound OC(=O)C(C)N(CC(O)=O)CC(O)=O CIEZZGWIJBXOTE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 239000004133 Sodium thiosulphate Substances 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 229960003093 antiseptics and disinfectants Drugs 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 108091027881 NEAT1 Proteins 0.000 description 1
- 101100016034 Nicotiana tabacum APIC gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000980 acid dye Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- PWZFXELTLAQOKC-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide;tetrahydrate Chemical compound O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O PWZFXELTLAQOKC-UHFFFAOYSA-A 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000006556 fastidious anaerobe broth Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003406 mycobactericidal effect Effects 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Abstract
An aqueous biocidel composition comprises: 0.5-5% by weight of a chelating component comprising one or more chelating agents or salts thereof; from 0.44% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants; amphoteric surfactants and mixtures thereof; and from 0.6-5% by weight of a quaternary ammonium component comprising one or more trialkyl benzylammoolurn salts having at least one C5-C20alkyl substituent, wherein the surfactant component and quaternary ammonium component are different from each other. The chelating component may comprise trisodium nitrilotriacetic acid.
Description
COMPOSITION
The present invention relates to an aqueous biocidal composition. In particular, the invention relates to an aqueous biocidal composition that is suitable for killing, inhibiting or preventing the growth of spores of Clostridium difficile.
Antiseptics and disinfectants are used extensively in hospitals and other health care settings for a variety of topical and hard-surface applications. In particular, they are an essential part of infection control practices and aid in the prevention of nosocomial infections12. Mounting concerns over the potential for microbial contamination and infection risks in the food and general consumer markets have also led to increased use of antiseptics and disinfectants by the general public. A wide variety of active chemical agents (or "biocides") are found in these products, many of which have been used for hundreds of years for antisepsis, disinfection, and preservation3.
A bacterium causing increasing concern is Clostridium difficile. C. difficile is a commensal bacterium of the human intestine in a minority of the population4. For C. difficile to establish itself and proliferate in the colonic mucosa, the normal flora of the colon must be disrupted (antibiotic use is the major cause) and C. difficile must be ingested56. Once established, C. diffidile is associated with gastrointestinal infections ranging in severity from asymptomatic colonization to severe diarrhoea, life-threatening pseudomembranous coUtis, fulrninant coUtis, toxic megacolon and intestinal perforation5.
Their spores are resistant to all antibiotic, commonly used disinfectants such as alcohol, heating and drying478. C. diffidile spores can survive up to 5 months in the environment6. S... * S * S. S
It has been observed that several disinfectarits commonly used in hospitals may fail to kill the bacteria C. duff/cue, and may actually promote spore formation. * . S S. *
Hence, there is a need for new biocidal compositions for use in hospital environments having a broad spectrum efficacy. In particular, there is a need for new biocidal S...
compositions that are capable of killing the spores of C. difficile.
US 7,192,601 relates to a germicidal composition which is stated to have enhanced microbiocidal activities for killing microbiological spores, microbiological outgrowth from spores, and vegetative microorganisms.
The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.
s According to a first aspect of the invention, there is provided an aqueous biocidal composition comprising: i. from 0.5 to 5% by weight of a chelating component comprising one or more chelating agents or salts thereof; ii. from 0.4 to 4% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and iii. from 0.6 to 5% by weight of a quaternary ammonium component comprising one or more trialkyl benzylammonium salts having at wherein the surfactant component and quaternary ammonium component are different from each other.
In a second aspect, there is provided a container comprising an aqueous biocidal composition according to the first aspect of the invention.
In a third aspect of the invention, there is provided a wet wipe impregnated or coated with an aqueous biocidal composition according to the first aspect of the invention.
In a fourth aspect of the invention, there is provided a process for the preparation of an aqueous biocidal composition according to the first aspect of the invention, comprising forming a mixture comprising the chelating component, the surfactant component and the quaternary ammonium component. * S *
In a fifth aspect of the invention, there is provided the use of an aqueous biocidal composition according to the first aspect of the invention as an in vitro anti-microbial agent. S...
SS S * . .
* Figures 1 and 2 are photographs of slides of Cleaning Test 1, Figures 3 to 6 are photographs of tiles of Cleaning Test 2, Figure 7 is a photograph of slides of Cleaning Test 3, and Figures 8 and 9 are photographs of slides of Cleaning Test 4.: The present invention is based in part on the surprising finding that a quatemary arnmonium-based composition shows efficacy against the spores of C. diffidile. The compositions of the invention may have one or more advantages compared to known anti-microbial agents that demonstrate efficacy against the spores of C. diffidile, the most commonly used being hypochlorite. For example, the composition of the invention is virtually odourless, is less damaging to surfaces, is safer to personnel and/or provides residual protection on hard surfaces for up to 5 days after treatment, preferably up to 10 days, such as up to 15, 20 or 25 days, most preferably up to 28 days after treatment.
io The term "biocida!" as used herein refers to an anti-microbial agent suitable for killing, inhibiting (at least in part, e.g.,10%, 20%, 50%, or 100% growth inhibition) or preventing the growth of micro-organisms such as bacteria, viruses, fungi and/or protozoa.
The biocidal composition of the invention is an aqueous biocidal composition. The term "aqueous" as used herein describes a water-based solution comprising at least 5% by weight water, for example at least 10%, preferably at least 25%, such as at least 50% or at least 75%, most preferably at least 95% such as at least 99%, by weight of water.
The aqueous biocidal composition of the present invention comprises a chelating component comprising one or more chelating agents or salts thereof. Preferably, the chelating component comprises or consists of one or more chelating agents selected from the group consisting of nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), N-(hydroxyethyl)-ethylenediaminetriacetic acid (HEDTA), methylglycinediacetic acid (MGDA), hydroxyethyliminodiacetic acid (HEIDA), glutaric acid-N,N-diacetic acid (GLDA), iminodisuccinic acid (IDS) or salts thereof. Suitable salts include, for example, sodium, potassium, ammonium or amine salts. Sodium salts are particularly preferred.
A particularly preferred chelating agent for use in the aqueous biocidal composition is :::: trisodium nitrilotriacetic acid (Na3NTA). Thus, the chelating component preferably comprises or consists of Na3NTA. In a particularly preferred embodiment, Na3NTA is the sole chelating agent in the composition of the invention. I...
The chelating component constitutes from 0.5 to 5% by weight of the composition, preferably from I to 4.5% by weight, such as from 1.5 to 4% by weight, more preferably from 2 to 3.5% by weight or from 2 to 2.5 % by weight (e.g., 2.27% by weight) of the composition.
The aqueous biocidal composition comprises a surfactant component comprising one or more surfactants selected from non-ionic surfactants (e.g. alkoxylated alcohols, alkyiphenols, amides, amines, esters, fatty acids or glycerides; alkanolamides, amine oxides, esters and/or alkyl polyglucosides), amphoteric surfactants (e.g. betaines, glycinates, propionates, acetates and/or imidazolines) and mixtures thereof.
Preferably, the surfactant component comprises or consists of one or more alcohol ethoxylates having an alkyl group with a pendant chain of the structure (OCH2CH2)mOH, wherein m is from 3 to 20, more preferably from 4 to 15, most preferably from 5 to 10 (such as 7). The alkyl group is preferably a C4-C20 alkyl, more preferably a C8-C18 alkyl or a C10-C16 alkyl, most preferably a C13-C15 alkyl, which may be linear or branched, cyclic or acyclic. For example, the alcohol ethoxylates may be derived from a primary, secondary or tertiary alcohol. Preferably, the alkyl group is an unsubstituted alkyl, more preferably a straight chained, unsubstituted alkyl. In a particularly preferred embodiment, the surfactant component comprises or consists of one or more alcohol ethoxylates having a C13-C15 alkyl group with a pendant chain of the structure (OCIf2CH2)mOH, wherein mis from 5 to 10.
The surfactant component constitutes from 0.4 to 4% by weight of the composition, preferably from 0.5 to 3.5% by weight, more preferably from 0.7 to 3% by weight, such as from 0.9 to 2.5% by weight, most preferably from I to 2% by weight or from 1.25 to 1.75% by weight (e.g., 1.45% by weight) of the composition.
The aqueous biocidal composition comprises a quatemary ammonium component comprising one or more trialkyl benzylammonium salts having at least one C5-C20 alkyl substituent. The alkyl substituent may be linear or branched, cyclic or acyclic.
Preferably, the alkyl group is an unsubstituted alkyl, more preferably a straight chained, unsubstituted alkyL In a preferred embodiment the quaternary ammonium component comprises or consists of one or more trialkyl benzylammonium salts having at least one C12-C15 alkyl substituent. Suitable salts include, for example, chloride, bromide, iodide and methosulphate. Chloride salts are particularly preferred. S. S * S*
* In a preferred embodiment, the trialkyl benzylammonium salts for use in the aqueous biocidal composition of the invention include the chloride salts of alkyldimethylbenzylammonium having a C-C.6 alkyl substituent and dialkylmethylbenzylammonium having at least one C12-C16 alkyl substituent. Most
S
preferably, the quaternary ammonium component comprises or consists of one or more chloride salts of alkyldimethylbenzylammoniUm having a C12-C16 alkyl substituent.
The quaternary ammonium component constitutes from 0.6 to 5% by weight of the composition, preferably from I to 4.5% by weight, such as from 1.5 to 4% by weight, more preferably from 2 to 3.5% by weight or from 2.5 to 3% by weight (e.g., 2.83% by weight) of the composition.
In a preferred embodiment, the aqueous biocidal composition comprises: (i) from I to 4.5% by weight of a chelating component comprising one or more chelating agents or salts thereof; (ii) from 0.5 to 3.5% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and (iii) from Ito 4.5% by weight of a quaternary ammonium component*comprising one or more trialkyl benzylammonium salts having at least one C6-C20 alkyl substituent, wherein the surfactant component and quatemary arnmonium component are different from each other.
* 20 In another preferred embodiment, the aqueous biocidal composition comprises: (i) from 2 to 3.5% by weight of a chelating component comprising one or more chelating agents or salts thereof; (ii) from I to 2% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and (iii) from 2 to 3.5% by weight of a quaternary ammonium component comprising one or more trialkyl benzylammonium salts having at least one C6-C20 alkyl substituent, wherein U' surfactant component and quatemarv ammonium component are different from each other.
In another preferred embodiment, the aqueous biocidal composition comprises: *:*. (i) from 1 to 4.5% by weight of a chelating component, wherein the chelating component comprises or consists of Na3NTA; (ii) from 0.5 to 3.5% by weight of a surfactant component, wherein the surfactant component comprises or consists of one or more alcohol ethoxylates having a C13-C15 alkyl group with a pendant chain of the structure -(OCH2CH2)OH, wherein mis from 4 to 15; and (iii) from 1 to 4.5 % by weight of a quaternary ammonium component, wherein the quaternary ammonium component comprises or consists of one or more chloride salts of alkyldimethylbenzylammoniurn having a C12-C16 alkyl substituent, wherein the surfactant component and quatemary arnmonium component are different from each other.
In a particularly preferred embodiment, the aqueous biocidal composition comprises: (i) from 2 to 3.5% by weight of a chelating component, wherein the chelating component comprises or consists of Na3NTA; io (ii) from I to 2% by weight of a surfactant component, wherein the surfactant component comprises or consists of one or more alcohol ethoxylates having a C13-C15 alkyl group with a pendant chain of the structure (OCH2CH2)mOH, wherein m is from 5 to 10; and (iii) from 2 to 3.5% by weight of a quaternary ammonium component, wherein the quatemary ammonium component comprises or consists of one or more chloride salts of alkyldimethylbenzylammonium having a C12-C16 alkyl substituent, wherein the surfactant component and quatemary ammonium component are different from each other.
In another particularly preferred embodiment, the aqueous biocidal composition comprises: (I) from 2 to 2.5% by weight of a chelating component, wherein the chelating component comprises or consists of Na3NTA; (ii) from 1.25 to 1.75% by weight of a surfactant component, wherein the surfactant component comprises or consists of one or more alcohol ethoxylates having a C13-C15 alkyl group with a pendant chain of the structure (OCH2CH2)mOH, wherein m is from 5to 10; and :::: (iii) from 2.5 to 3.0% by weight of a quaternary ammonium component, wherein the quaternary ammonium component comprises or consists of one or more chloride salts of alkyldimethylbenzylammonium having a C12-C16 alkyl substituent, wherein the surfactant component and quatemary ammonium component are *.** different from each other.
Preferably, the aqueous biocidal composition comprises one or more additional components, such as rheology modifiers, fragrances and colouring agents (e.g., acid dyes such as Cl acid blue 80). These optional components may be present in the composition of the invention in an amount of less than 1 % by weight, such as less than 0.5% or less than 005% or less than 0.005% by weight.
In a preferred embodiment, the aqueous biocidal composition further comprises components which may enhance the anti-microbial activity of the composition. These further components may include, for example, solvents (such as alcohols and/or glycol ethers) and/or alkalis (such as hydroxides, carbonates, phosphates, silicates and/or amines).
io The aqueous biocidal composition of the invention may be in any suitable form, such as, for example, a liquid or foam.
According to the second aspect of the invention, there is provided a container comprising an aqueous biocidal composition according to the first aspect of the invention. The container preferably comprises a spray nozzle, which facilitates the formation of spray to distribute the aqueous biocidal composition over an area. For example, the composition of the invention may be packaged and sold in the form of a hand operated spray (eg., a trigger spray) or a pressurised aerosol spray.
The third aspect of the invention provides a wet wipe. Thus, in one embodiment, the composition of the invention may be packaged and sold in the form of a wet wipe i.e., a cloth or fabric which is impregnated or coated with the aqueous biocidal composition of the invention.
According to the fourth aspect of the invention, there is provided a process for preparing the biocida! composition according to the first aspect of the invention, comprising forming a mixture comprising the chelating component, the surfactant component and the auatemarv ammonium comoonent. * * * * a
Thus, compositions of the invention will typically be prepared by dissolving the constituent components in water to the desired concentration. In one embodiment, the *...
*:*. constituent components are provided in the form of a concentrate comprising: from 5 to 20% by weight of a chelating component comprising one or more chelating agents or salts thereof; ii. from 2 to 15% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and iii. from 5 to 20% by weight of a quatemary ammonium component comprising one or more trialkyl benzylammonium salts having at least one wherein the surfactant component and quaternary ammonium component are different from each other.
The preferred features of the chelating component, the surfactant component and the quatemary ammonium component are as defined in respect of the first aspect of the invention.
It will be appreciated that the concentrate may be provided in any suitable form, such as a solid (e.g., as a powder or granulate) or as a liquid.
The concentrate may be prepared using methods well know in the art. For example, a powder or granular concentrate may be prepared by blending the constituent components to produce a homogeneous mixture. This may be achieved, for example, simply by mechanically stirring the mixture for a suitable amount of time. Alternatively, a liquid concentrate may be produced by dissolving the constituent components in water to the desired concentration.
The aqueous biocidal composition of the invention may be used as a anti-microbial agent, particularly in the biomedical and/or healthcare fields. For example, the composition may be used in the form of a single stage disinfecting solution or wash to kill or prevent the growth of microorganisms on a surface or substrate, such as in a clinical environment (e.g. surgical theatre) or a domestic environment (e.g. a kitchen work surface). In all cases, the composition may be applied to the surface to be disinfected. * S..
Thus, the invention also contemplates the use of the aqueous biocidal composition according to the first aspect of the invention as an in vitro anti-microbial agent. For example, the composition may be used for killing, inhibiting or preventing the growth of bacteria, viruses, fungi and/or protozoa. The bacteria may be Gram-positive or Gram- negative bacteria. Thus, the bacteria may be, for example, selected from the group consisting of Mycobacteria spp. (e.g., Mycoba cterium tuberculosis, Mycobacterium terrae, Mycobacterium avium or Mycobacterium Bovis), Staphylococcus spp. (e.g., methicillin-resistant Staphylococcus aureus), Clostridium spp. (e.g., Clostridium difficile) and Enterococcus spp. (e.g., ye nconiycin-resistant Enterococcus).
In one embodiment, the bacteria are spore forming. For example, the composition of the invention may be used for killing, inhibiting or preventing the growth of spores of Clostridium difficile.
In an alternative embodiment, the composition of the invention may be used for killing, inhibiting or preventing the growth of viruses. The viruses may be selected, for example, from the group consisting of norovirus, influenza (e.g., human or aviari influenza), human imrnunodeficiency virus, Hepatitis B virus and Hepatitis C virus.
In another embodiment, the composition of the invention may be used for killing, inhibiting or preventing the growth of fungi. The fungi may be selected, for example, from Penicillium spp., Candida spp. (e.g., Candida albicans) and Aspergillus spp. (e.g., Aspergillus niger).
The composition of the invention can be applied to a surface or object to be disinfected using any suitable technique known in the art. For example, the composition may be sprayed onto a surface (in the form of a liquid or foam) or transferred onto a surface using, for example, an absorbent paper, cloth, sponge, mop or using the wet wipe described herein. Alternatively, objects to be disinfected may be immersed in the composition of the invention, the composition being optionally agitated. In yet another method of application, the composition may be diffused into the atmosphere of a closed area, for example, by means of diffusion/fogging equipment. Alternatively, the composition may be released into the atmosphere by using an aerosol can that is able to discharge its contents into the surrounding atmosphere in a single rapid discharge.
The following non-limiting examples illustrate the invention but do not limit its scope in any way. In the examples and throughout the specification, all percentages, parts and :::: ratios are by weight un!ess indicated otherwise. It will be appreciated that the various percentage amounts of the different components that are present in the products of the invention, including any optional components, will add up to 100%.
S S...
Examples
Example I
Comparative study of the sporicidal activity of a biocidal composition of the invention, Peracetic acid and Sodium hypochiorite (bleach) against Clostridium difficile Samples tested The three products tested were a biocidal composition of the invention (Composition A), a proprietary peracetic acid based formulation, and a sodium hypochiorite based product.
The exemplary biocidal composition of the invention (Composition A) had the following composition: Component CAS number Weight % Trisodium nitrilotriacetate 5064-31-3 2.27 (as active Na3NTA) ______________ __________ Alcohol ethoxylate (as 681 31-39-5 1.45 active) Cl 3-15 7E0 _____________ _________ Benzalkonium chloride (as 68424-85-1 2.83 active) C12-16 alkyl dimethyl _________________ ____________ Cl acid blue 80 ______________ 0.000252 Water _____________ To 100 Preparation of inoculums The test strain used was Clostridium difficile, NCTC 11209. An overnight culture of NCTC 11209 was grown up in fastidious anaerobe broth at 37°C and the final count ascertained by the surface drop (Miles and Misra) technique, incubated in an anaerobic * * * jar. **** * S I...
Test for residual activity S... * . S S. S
A 1 ml volume of the Composition A was pipetted and spread over a defined area of 5 x 5 cm (25 cm2) and allowed to dry in a laminar flow cabinet, On the tile there were eight 5 x : : 5 cm2 squares each receiving I ml of Composition A. The squares were labelled neat 0 * 25 hrs, neat 4 hrs, neat day 7, neat day 28, -2 dilution 0 his, -2 dilution 4 hrs, -2 dilution day 7 and -2 dilution day 28. The same was carried out with the peracetic acid based formulation at 5%vfv dilution and the sodium hypochiorite at 10%v/v dilution.
The peracetic acid product was tested at 5%vlv dilution. The product manufacturers recommend the product to be used at 3-5%, therefore the product was tested at the highest concentration, The sodium hypochlorite sample was a nominal 10% available chlorine product. This was tested at 10%v/v, which means that the final concentration of the test solution was 10000 ppm of available chlorine.
A volume of 0.1 ml of a neat Clostridium difficile suspension containing a known number of colony forming units was spread over the neat 0 hrs square on the Composition A, peracetic acid and sodium hypochlorite tile. 0.1 ml of a -2 dilution from the neat Clostridium difficile was spread on the -2 dilution 0 hr square on the Composition A, peracetic acid and sodium hypochiorite tile. For each chemical, the tile was swabbed 5 minutes after inoculation to determine the level of surviving organisms. Each swab was then placed in 10 ml of TLTR neutralising solution (containing Tween 80, lecithin, sodium thiosulphate, ringers and maximum recovery diluent), pulverised vigorously, then plated onto blood agar plates using 0.5 ml, 0.1 ml and lOpI volumes.
The TLTR neutralising solution is the standard neutralising solution used in the HPA-WEMS laboratory for challenge and residual activity testing.
Once the inoculum had been absorbed, the plates were incubated in an anaerobic jar at 37°C for 18-24 hours, and the number of colonies counted and recorded.
Four hours after the initial inoculation of the tiles, 0.1 ml of the same neat and -2 Clostridium difficile overnight suspension was spread over a new defined 5 x 5 cm (25 cm2) area, neat 4 hrs for the neat Clostridium difficile and -2 dilution 4 hrs for the -2 Clostridium diffidile dilution, on each tile, and the same method as above was followed.
**** One week later, and again at day 28, each tile was reinoculated in the same way using a fresh neat and -2 dilution C!ostridium di.. ic/Is suspension and the procedure previously described repeated.
A control was carried out by pipetting 0.1 ml of a neat Clostridium difficIle suspension *:*. onto a defined 5 x 5 cm (25 cm2) area on a tile with no chemicals added. After 5 minutes, the tile was swabbed, placed in 10 ml of TLTR neutratising solution, pulverised vigorously, then plated onto blood agar plates and incubated in an anaerobic jar with the test plates.
S
Results
Table I
Recovery of Clostridium difficile from coated tiles Number of Inoculum level Chemical used Recovery after 5 rain hours/days of *Clostridium on tile Colony log reduction* following d!fficile forming coating (cfu/O.lml) units/swab 0 hours I.2x1 Composition A 1.OxI 00 6.8 5.7x1 Peracetic acid 1.2x1 2.6 5.7x107 Sodium 4.0x104 3.1 hypochiorite 4hours I.4x107 CompositionA <1 7.1 5.7x107 Peracetic acid 1.1x106 1.7 5.7x107 Sodium 2.2xI0 1.4 hypochlorite Day7 6.0x105 CompositionA 2,OxIO° 5.4 I.lxl 06 Peracetic acid 2,6x1 0.6 :::: I.1x106 Sodium 3.4x105 0.5 hypochlorite **.* Day 28 I.2x10' Composition A <1 7.1 2.7x107 Peracetic acid 68x106 0.6 2.7x107 Sodium 65x106 0.6 hypochlorite Control 1.0x107 39x106 0.4 * 1 log reduction is equivalent to a 10 fold drop in numbers
Table 2
Colony counts on plates Chemical Time Dilution Count on plate Period Factor 0.5 ml 0.1 ml 0.01 ml spread spread spread Composition A 0 hr Neat 1 0 0 Composition A 0 hr -2 0 0 0 Composition A 4 hr Neat 0 0 0 Composition A 4 hr -2 0 0 0 Composition A 7 day Neat 2 0 0 Composition A 7 day -2 0 0 0 Composition A 28 day Neat 0 0 0 Composition A 28 day -2 0 0 0 Peracetic acid 0 hr Neat TNTC TNTC 400 Peracetic acid 0 hr -2 25 12 2 Peracetic acid 4 hr Neat TNTC TNTC 450 Peracetic acid 4 hr -2 TNTC 110 18 Peracetic acid 7 day Neat TNTC TNTC 111 Peracetic acid 7 day -2 TNTC 26 4 Peracetic acid 28 day Neat TNTC TNTC TNTC Peracetic acid 28 day -2 TNTC TNTC 68 Sodium hypochbrite 0 hr Neat TNTC TNTC 450 *S..
: Sodium hypochlorite 0 hr -2 20 5 0 Sodium hypochlorite 4 hr Neat TNTC TNTC TNTC i.e. Sodium hypochlorite 4 hr -2 TNTC 80 22 : Sodium hypochlorite 7 day Neat TNTC TNTC 34 Sodium hypochlorite 7 day -2 TNTC 14 0 Sodium hypochlorite 28 day Neat TNTC TNTC TNTC Sodium hypochlorite 28 day -2 TNTC TNTC 65 TNTC = Too numerous to count
S
Discussion For the zero hour time period for the three tiles inoculated with the Clostridium diffidile organism, the sodium hypochiorite covered tile produced a 3.1 log reduction in counts.
The peracetic acid covered tile returned a 2,6 log reduction in counts and the tile covered in Composition A returned a 6.8 log reduction in counts. The actual counts for each plate can be seen in Table 2 above.
After the tiles had been coated with the three chemicals for 4 hours, the microbial counts (Clostridium difficile) returned for the Composition A tile gave a 7.1 log reduction, but it had fallen for the sodium hypochlorite (a 1.4 log reduction in actual counts) and for the peracetic acid (a 1.7 log reduction in actual counts). When the tiles were re-inoculated with Clostridium difficile one week later, the Composition A tile log reduction was 5.4 log.
This log reduction is lower than at the other 3 time points due to the initial Clostridium difficile inoculum being only colony forming units (cfu) compared to i07 cfu at 0 hours, 4 hours and 28 days. The sodium hypochlorite tile had fallen to a 0.5 log reduction in counts, while the peracetic acid tile had a 0.6 log reduction in counts.
After 28 days, the log reduction, for Clostridium difficile, for the Composition A tile was 7.1 log in counts. The sodium hypochiorite overall log reduction had fallen to 0.6 log in counts while the peracetic acid overall log reduction was also 0.6 log in counts.
The control result shows that there is a 0.4 log recovery reduction using the above method when no disinfectant is added to the tile On the tile dosed with sodium hypochiorite, it was also noticed that on the 4 hour, day 7 and day 28 testing times, the bleach had dried and left behind a grainy white crusty U * 0 I. S
Conclusion 0**S S...
Results on day 0 after the first challenge indicate that Composition A coated onto a tile is most effective in reducing very high levels (1O cfu) of Clostridium difficile within 5 minutes. The sodium hypochlorite based formulation is the next most effective, with the peracetic acid based formulation the least effective. Following re-inoculation of Closfridium duff/cue at various time periods, residual activity could still be demonstrated 28 days after the Composition A coating was applied to the tiles. The log reduction is slightly lower after day 7 but this is due to a lower initial concentration of Clostridium duff/cue compared to the other time points. in comparison, with sodium hypochlorite the log reduction has fallen from 3.1 log to 0.6 log, and with the peracetic acid based formulation from 2.6 log to 0.6 log over this tine.
Comparative Example 2 Assessment of the activity against Clostridium Difficile Sample tested Composition B having the following composition: Component CAS number Weight % Trisodium nitrilotriacetate (as 5064-31-3 7.2 active Na3NTA) ________________ ____________ Alcohol ethoxylate (as active) 68131-39-5 4.61 C13-157E0 _____________ __________ Benzalkonium chloride (as 68424-85-1 9.0 active) C12-16 alkyl dimethyl ________________ ____________ Cl acid blue 80 ________________ 0.0008 Water ________________ To 100 Appearance of sample Clear blue solution Storage conditions I..' * S S ** . * ass Room temperature, in a dry place out of direct sunlight. *5
e... : Test organisms *** Clostridiurn duff/cue NCTC 11209
I S... * 04
1 Test method and validation No European Phase 2/ Step 1 test has as yet been described to establish sporicidal activity of chemical disinfectarits against Clost rid/urn duff/cue in the medical area. The only Phase 2/ Step 1 test published to date is EN 13704 which is designated for food, industrial, domestic and industrial areas. This test looks for a > 3 log10 reduction in 60 minutes under clean conditions only. The test product Composition B was tested against C. difficile spores following the test conditions described in other Phase 2/ Step I tests for the medical area, Sample test concentration 5% solution in standard hard water Contact times 1, 5, 10, 15, and 30 minutes.
An additional contact time of 60 minutes was included to meet the mandatory test criteria.
Test temperature 20°C Interfering substance Clean conditions -0.03 % bovine albumin (final concentration).
Dirty conditions -0.3 % bovine albumin (final concentration) plus 3% washed sheep erythrocytes. * 0
Inhibition method *0 * Dilution/neutralization S...
S S...
. : Neutralizer * *.
Tween 80 (30g1 L), Sodium Lauryl Sulphate (4g1 L), Lecithin (3g/ L).
Tests were performed to establish the suitability of this neutralizer in inhibiting the activity of the disinfectant without being toxic to the test organisms (method described in EN 14348).
Summary of the test methods
The disinfectant was prepared in accordance with EN 13704, in sterile hard water, immediat&y prior to testing.
A suspension of Clostridium difficile was prepared, containing at least viable sporesIml. The EN 13704 test method involves mixing I nil of the test bacteria with 1 ml of soil (0.3% albumin or 3% albumin plus 3% sheep erythrocytes) and then adding 8 ml of test disinfectant. After the required contact time, I ml is removed to 9 ml of recovery broth (8m1 neutralizer and I ml diluent). Surviving test bacteria were detected by plating onto blood agar and incubated anaerobically for 3 -5 days.
Requirement The test requirements for EN 13704 (Phase2 Step I sporicidal test) is for a 3 log10 reduction in 60 minutes.
Results
Table 3
Sporicidal activity of Composition B under clean and dirty conditions S * S S. S ** Log10 Initial Contact Log10 Reduction Achieved Count Time Clean Conditions 1 Dirty Conditions (Challenge) (0.03 % Albumin) (0.3 % Albumin pius 3% : ________ ________ ________ Sheep er thocytes ________ ___________ _________ Test I Test 2 Mean Test I Test 2 Mean 1 mm 0.85 0.79 0.82 0.70 0.61 0.66 mm 0.91 0.92 0.92 0.89 0.99 0.946 : 6si 10mm 1.01 0.98 1.00 1.17 1.15 1.166 : 15mm 1.58 1.25 1.42 1.53 1.57 1.556 * S. 30 mm 0.48 0.55 0.52 1.23 1.36 1.30 __________ 60 mm 0 0.08 004 0.80 0.82 0.81 All tests were carried out in duplicate.
Conclusion
Composition B does not demonstrate sporicidal activity at 20°C under clean (0.03% albumin) and dirty (0.3% albumin! 0.3% sheep erythrocytes) conditions against Clostridium difficile spores.
Published EN tests for sporicidal activity have a requirement for a 3 log10 reduction in 60 minutes. This was not achieved after a contact time of 60 minutes under either clean or dirty conditions; therefore Composition B failed the test criteria.
Example 3
Assessment of the activity of a biocidal composition of the invention against Clostridium Difficile Sample tested Biocidal composition of the invention (Composition A) having the following composition: Component CAS number Weight % Trisodium nitrilotriacetate 5064-31-3 2.27 (as active Na3NTA) _______________ ___________ Alcohol ethoxylate (as 68131-39-5 1.45 active) C13-15 7E0 ______________ __________ Benzalkonium chloride (as 68424-85-1 2.83 active) C12-16 alkyl dimethyl ________________ ____________ Cl acid blue 80 _______________ 0.000252 Water _____________ To 100 Comparative tests were carried out using a proprietary chlorine releasing agent at *..* : 20 l000ppm. *S.. * * **. S
Appearance of product * S ** . Clear blue solution Storage conditions S...
*:*. Room temperature, in a dry place out of direct sunlight.
Test organisms Clostridium difficile NCTC 11209 Test method and validation No European Phase 2/ Step 1 test has as yet been described to establish sporicidal activity of chemical disinfectants against Clostridium difficile in the medical area. The only Phase 2/Step 1 test published to date is EN 13704 which is designated for food, domestic and industrial areas. This test looks for a > 3 log10 reduction in 60 minutes under clean conditions only. The test product "Composition A" was tested against C. difficile spores using the test conditions ie temperature, organic load, described in other Phase 2/ Step 1 tests for the medical area.
Contact times 5, 10,20 and 30 minutes. An additional contact time of 60 minutes was included to meet the mandatory test criteria.
Test temperature 20°C Interfering substance Clean conditions -0.03 % bovine albumin (final concentration).
Dirty conditions -0.3 % bovine albumin (final concentration) plus 3% washed sheep erythrocytes.
Inhibition method Dilution/neutralization S...
: Neutalizer *::::* Composition A: Tween 80 (30g/ L), Sodium Lauryl Sulphate (4g1 L), Lecithin (3g/ L).
Chlorine releasing agent: Tween 80 30g/1, lecithin 3g/1, sodium thiosulphate 7.5g11, Histidine lg/l, Saponin 30g/l, TSB 30g/l. S...
: Tests were performed to establish the suitability of this neutralizer in inhibiting the activity * U. of the disinfectant without being toxic to the test organisms (method described in EN 14348).
S
Summary of the test method
A suspension of Clostridium difficile was prepared, containing at least viable spores/mi.
The EN 13704 test method involves mixing I ml of the test bacteria with 1 ml of soil (0.3% albumin or 3% albumin plus 3% sheep erythrocytes) and then adding 8 ml of test disinfectant. After the required contact time, 1 ml is removed to 9 ml of recovery broth (8m1 neutralizer and I ml diluent). Surviving test bacteria were detected by plating onto io blood agar and incubated anaerobically for 3 -5 days.
Requirement The test requirements for EN 13704 (Phase2 Step I sporicidal test) is for a 3. log10 reduction in 60 minutes.
Results
Table 4
Sporicidal activity of Composition A under clean and dirty cDndtions Log10 Reduction Achieved Log10 Clean Conditions Dirty Conditions Initial Contact (0.03 % Albumin) (0.3% Albumin plus 3% Count Time ________ ________ ________ Sheep_erythocytes) (Challenge) Test I Test 2 Mean Test I Test 2 Mean mm 2.45 2.15 2.30 2.27 2.35 2.31 mm 2.58 2.63 2.61 2.45 2.45 2.45 6.51 20 mm 3.59 3.55 3.57 3.51 3.30 3.41 mm 4.60 4.75 4.68 4.43 4.55 4.49 __________ 60 mm 4.96 5.05 5.01 5.05 5.09 5.07 * * * ** * All tests were carried out in duplicate. **** * *.SI ** * * * * * I.
Table 5
Sporicidal activity of a chlorine releasinQ apent (l000ppm) under clean and dirty cDnditions Logi0 Reduction Achieved Logia Clean Conditions Dirty Conditions Initial Contact (0.03 % Albumin) (0 3% Albumin) Count Time Test I Test2 Mean Test I Test 2 Mean - (Challenge) mins >6.83 >6.83 >6.83 >6.83 >6.83 ->6.83 - mins >6.83 >6.83 >6.83 >6.83 >6.83 >6.83 - 7.83 20 mins >6.83 >6.83 >6.83 >6.83 >6.83 >6.83 - __________ 30 mins >6.83 >6.83 >6.83 >6.83 >6.83 >6.83 __________ 60 mins] >6.83 >6.83 >6.83 >6.83 I >6.83 ________ All tests were carried out in dupUcate.
Conclusion
Tests carried out with Composition A demonstrated activity against spores of Clostridium difficile at 20°C under clean (0.03% albumin) and dirty (0.3% albumin! 0.3% sheep erythrocytes) conditions.
Published EN tests for sporicidal activity i.e. EN 13704 have a requirement for a 3 log is reduction in 60 minutes. This was achieved after a contact time of 20 minutes under clean or dirty conditions; therefore Composition A fulfils the test criteria.
Example 4 * S 5.*
Soil removal efficiency *..e * * S S. I Samples tested A biocidal composition of the invention (Composition A) was compared with l000pprn Chlorine and 10,000ppm Chlorine from liquid bleach (NaClO) and bleach tablets . .: (NaDCC).
Composition A (also referred herein as Anovium) had the following composition: Component CAS number J Weight % Trisodium nitrilotriacetate 5064-31-3 2.27 (as active Na3NTA) ______________ __________ Alcohol ethoxylate (as 68131-39-5 1.45 active) CI 3-15 7E0 _____________ _________ Benzalkonium chloride (as 68424-85-1 2.83 active) C12-16 alkyl dimethyl ________________ ___________ Cl acid blue 80 _______________ 0.000252 Water ______________ To 100 Cleaning Test I Test Soil: Whole Milk Test Surface Preparation: A Stilbene Derivative Optical Brightener was added to the soil (Whole milk) before it was applied to the test surfaces. The test surfaces used in this test were 38mm x 76mm glass slides. The soil was applied to 6 slides by pipette. I ml of soil was drawn across each test surface. The slides were then stood up and 1 ml of soil was allowed to run over the test surface to cover. The slides were then allowed to dry at room temperature.
Products under test: Sample Reference Test Product Concentration Source *:::: A Composition A 100% Composition A B Chlorine l000ppm Cl Chlorine tablets (NaDCC) C Chlorine 10000ppm Cl Chlorine tablets (NaDCC) D Chlorine l000ppm Cl Liquid bleach *.S. -: (NaClO) E Chlorine 10,000ppm Cl Liquid bleach (NaCIO) F Control No cleaning process carried out on this slide Test Procedure: The test was carried out at ambient temperature. SOmI of each test product were placed in lOOrni beakers. Each slide was placed in the corresponding beaker to soak. After 3 seconds, the slides were removed from the beakers and rinsed under a running water tap at a constant flow. Each slide in turn was then dipped back into the test solution and the treated area was wiped over 3 times with a 25mm pure bristle brush and the slides rinsed again. The slides were then left to dry.
Obtaining Results: The processed slides were photographed in a dark room under UV light to detect any soil residue left behind.
Photographic Results: It can be seen from Figure 1 that the slides cleaned with Chlorine at both l000ppm and 10000ppm still show a film of soil across the cleaned area. The slide cleaned with Composition A (Anovium) shows virtually no soil residue left on the cleaned area. The soil can be clearly seen on the control which was not subjected to cleaning.
Again it can be seen from Figure 2 that the slides cleaned with Chlorine show a film of soil residue, however, it can also be seen that the I O000ppm Chlorine from NaCIO has left less residue than the l000ppm and than the NaDCC Chlorine test slides.
Composition A (Anovium) shows virtually no residue of soil left on the cleaned area. The soil can be clearly seen on the control slide which was not subjected to cleaning.
Cleaning Test 2 * 25 *I.. * . *
Test Soil: Blood#1 * *S.* Test Surface Preparation: The test surfaces used in this test were 150mm x 150mm : white glazed ceramic tiles. 2ml of soil was applied to an area of 50mm x 150mm via pipette and drawn across the surface of the test area. Each tile was then stood vertically to allow excess liquid to drain off. The tiles were then allowed to dry at room **** temperature. * I S * *S
S
Products under test: Sample Reference Test Product Concentration 1 Source A Composition A 100% Composition A -B Chlorine 1 000ppm Cl Liquid bleach (NaCIO) C Chlorine 10,000ppm Cl Liquid bleach (NaCIO) D Chlorine 1 000ppm Cl Chlorine tablets (NaDCC) E Chlorine 10,000ppm CI Chlorine tablets (NaDCC) Test Procedure: The test was carried out at ambient temperature. Each test solution was sprayed onto a portion of the soiled tile using a mist sprayer (Internal reference: I25MLTK). The tiles were then left to dry.
Obtaining Results: The processed slides were photographed to enable assessment of any visual soil residue left behind.
Photographic Results: It can be seen in comparative Figures 3 to 6 that Composition A (Anovium) gave a better clean than the other test solution. In each Chlorine source, the I 0,000ppm solution gave a slightly inferior clean to the l000ppm solution. *.. S * S
Cleaning Test 3 **.. * * . S. S
Test Soil: Blood#2 Test Surface Preparation: The test surfaces used in this test were 150mm x 150mm S...
. : white glazed ceramic tiles. imI of soil was applied to an area of 50mm x 150mm via * *5 pipette and drawn across the surface of the test area. Each tile was then stood vertically to allow excess liquid to drain off. The tiles were then allowed to dry at room temperature. Once dried, the tiles were stored at 40°C for 15 hours. Before testing commenced the tiles were removed from 40CC conditions and allowed to cool at room temperature for 30 minutes.
Products under test: Sample Reference Test Product Concentration Source A Composition A 100% Composition A B Chlorine l000ppm Cl Chlorine tablets (NaDCC) C Chlorine 10,000ppni C! Chlorine tablets (NaDCC) D Chlorine l000ppm C! Liquid bleach (NaClO) E Chlorine 10000ppm Cl Liquid bleach (NaClO) Test Procedure: The test was carried out at ambient temperature. For each test solution, 4m1 was allowed to run over half of the soiled area under gravity with the tiles standing vertically. Each test surface was then rinsed under a running tap of standard speed.
The slides were then allowed to dry at room temperature.
Obtaining Results: The processed slides were photographed to enable assessment of any visual soil residue left behind.
Photographic Results: * 0e ***. * S
The results demonstrated by Figure 7 clearly show that Chlorine at 10,000ppm from NaDCC showed the least cleaning power. Composition A (Anovium) and 10,000ppm Chlorine from NaCIO showed to clean the best leaving behind the least quantity of soil.
Cleaning Test 4 S... * I S * .
Test Soil: Whole Egg Test Surface Preparation: A Stilbene Derivative Optical Brightener was added to the soil (Whole Egg) before it was applied to the test surfaces. The test surfaces used in this test were 38mm x 76mm glass slides. The soil was applied to 6 slides by pipette. 0.6g of soil was drawn across each test surface and the slides were allowed to dry at room temperature.
Products under test: Sample Reference Test Product Concentration Source A Composition A 100% Composition A B Chlorine I 000ppm Cl Chlorine tablets (NaDCC) C Chlorine 1 0,000ppm Cl Chlorine tablets (NaDCC) D Chlorine l000ppm Cl Liquid bleach (NaCID) E Chlorine 10,000ppm Cl Liquid bleach (NaCIO) F Control No cleaning process carried out on this slide Test Procedure: The test was carried out at ambient temperature. 5Oml of each test product were placed in lOOmI beakers. Each slide was placed in the corresponding io beaker to soak. After 30 seconds, the slides were removed from the beakers and rinsed under a running water tap at a constant flow. Each slide in turn was then dipped back into the test solution and the treated area was wiped over 3 times with a 25mm pure bristle brush and the slides rinsed again. The slides were then left to dry. The cleaning *::.: cycle was then repeated soaking each slide for 30 seconds, agitating with a brush and rinsing. The slides were then left to dry again at ambient temperature. I * II *
Obtaining Results: The processed slides were photographed in a dark room under UV light to detect any soil residue left behind. I.
I
Photographic Results: It can be seen from Figure 8 that the slides cleaned with Chlorine at l000ppm and Composition A (Anovium) have significantly less soil remaining on the cleaned area than the slide cleaned with 1D,000ppm Chlorine. The soil can be clearly seen on the control which was not subjected to cleaning.
It can be seen again from Figure 9 that the 10000ppm Chlorine solutions had inferior clean to the l000ppm Chlorine solution. Composition A (Anovium) showed the best clean leaving the smallest quantity of soil behind. The soil can be clearly seen on the control which was not subjected to cleaning.
Example 5
Feline Calici virus (Human Norovirus Surrogate) EN 14476:2005 Chemical disinfectants and.antiseptics -Virucidal quantitative suspension test for chemical disinfectants and antiseptics used in human medicine -Test method and requirements (phase 2lstep 1) Sample tested A biocidal composition of the invention (Composition A) having the following composition: Component CAS number Weight % Trisodium nitrilotriacetate 5064-31-3 2.27 (as active Na3NTA) ________________ ___________ Alcohol ethoxylate (as 68131-39-5 1.45 active) C13-15 7E0 ______________ __________ *I Benzalkonium chloride (as 68424-85-1 2.83 * * S is * active) C12-16 alkyt dimethyl _________________ ____________ **_ Cl acid blue 80 ____________ 0.000252 Water ______________ To 100
S S. *
Storage conditions Room temperature and darkness Product dituent Sterile Hard Water Product test concentrations 80% VN S. * S Se 25 Test Method arid its validation Method 1 part interfering substance + I part virus suspension + 8 parts biocide were mixed and incubated at the indicated contact temperature for the indicated contact times. Assays were validated by a cytotoxicity control, virotoxcity control and a formaldehyde internal standard.
Dilution-neutralization Neutralizer Dulbecco's modified Eagles medium + 5% v/v foetal bovine serum at 4°C.
Experimental Conditions Product diluent used Sterile Hard Water Product test concentration 80% VN Contact times 10 minutes,� lOs mir,utes� lOs Test temperature 20°C � 1°C Interfering substances 0.6 g/l foetal bovine serum + 0.03% VN BSA.
Temperature of incubation 37°C � 1°C + 5% CO2 .. : Identification of virus FELINE CALICIVIRUS/CRFK CELLS a... * .
Results * . S
S
Exposure Virus Virus Cytotoxicity 80% Time Recovery Recovery (80%) Composition S...
: 0mm 5mm A * . (TCID50/rnl) (TCID50/ml) (TCID50/ml) (TC!D50/ml) mm 3.16E+08 2.14E+08 3.16E+04 3.16E+04 3.1 6E+08 2. 14E�08 3.1 6E+04 3. 16E�04 LOG 8.50 8.33 4.50 4.50 LOG 3.83 Difference nun 3.1SE+08 2.14E+08 J 3.16E+04 3.16E+04 3.16E+08 2.14E+08 3.16E+04 3.15E+04 LOG 8.50 8.33 4.50 4.50 LOG 3.83 Difference
Conclusion
According to EN 14476: 2005, Composition A possesses virucidal activity at 80.0% VN against FELINE CALICIVIRUS at 20°C following 5 minutes contact under clean conditions.
Example 6
Activity against EN 14348 under clean' and dirty' conditions.
Sample tested A biocidal composition (Composition C) having the following composition: Component CAS number Weight % Trisodium nitrilotriacetate (as 5064-31-3 7.2 active Na3NTA) _________________ ____________ S...
: Alcohol ethoxylate (as active) 68131-39-5 4.61 C13-157E0 ______________ __________ S..... Berizalkonium chloride (as 68424-85-1 9.0 active) C12-16 alkyl dimethyl _________________ ____________ Clacidblue80 ______________ 0.0008 Water _____________ To 100 Product stored at room temperature in the dark. S...
* .* Experimental conditions: Product test concentrations -10% v/v Product diluent used during test -Sterile hard water 300mg/kg CaCO Contact time -5 mm Test Temperature -20°C � 0.5°C Interfering substance -As table NeutraUsing solution -3% Tween 80, 3% Saponin, 0.1% Histidine, 0.1% Cysteine Temperature of incubation -30°C � 1°C Identification of bacterial strains used -Mycobacterium terrae ATCC 15755 Test Results Validation test Mycobacterium terrae Bacterial suspension Vc 166, 134 Nv 1.50x Experimental conditions Vc 182, 154 A1.68x102 Neutraliser control Vc 160, 122 B 2.41 x 102 Dilution-neutralisation control Vc 144, 178 C 1.61 x 10 Bacterial Test Suspension 106 144 192 12 15 N 1.51 x 108 10% v/v Count at: 0.3g/l 3.Og/l serum I 6.Og/l serum I 9.Og/l serum Reduction bovine 3.Oml/lerythrocytes 6.Omlflerythrocytes 9.Oml/lerythrocytes in numbers serum mm 0 0 0 0 exposure minO 0 0 0 *: exposure . * 10 * * S * S. Vc = Viable Count.
N. = Number of cfulml of the bacterial test suspension.
Nv = Number of cfu in bacterial suspension.
R = Reduction in viability.
Na Number of cfu/ml in the test mixture
Conclusion
According to EN 14348 Composition C when diluted 1:10 in sterile hard water possesses satisfactory mycobactericidal activity in 5 minutes at 20°C under extreme dirty conditions (9.Og/l bovine albumin / 9.Dml/l sheep erythrocytes) for the reference organism detailed. * * *
S S... * S S... I... * . S I. S S... I* *
S SS S *S
REFERENCES
1. Larson, E. L. 1996. Antiseptics, p. 19-1-19-7, G1-G17. In R. N. Olmstad (ed.), APIC infection control & applied epidemiology: principles & practices. Mosby-Year Book Inc., St. Louis, Mo.
2. Rutala, W. A. 1995. APIC guidelines for selection and use of disinfectants. Am. J. Infect. Control 23:313-342.
3. Block, S. S. 1991. Historical review, p. 3-17. In S. S. Block (ed.), Disinfection terilization, and preservation, 4th ed. Lea & Febiger, Philadelphia, Pa.
4. Kuijper EJ et a!. Emergence of Clostridium diffici/e-associated disease in Canada, the United States of America and Europe. Second Concept March 31C1, 2006. Report from is European CDC www.ecdc.eu.intldocuments/pdf/Cl dif v2,pdf 5. Sunshine RH et a!. Clostridium diffici!e-associated disease: New challenges from an established pathogen. Cleveland Journal of Medicine (2006); 73(2): 187-97.
6. Tonna I et a!. Pathogenesis and treatment of Clostridium difficile infection.
Postgraduate Medical Journal (2005); 81: 367-9.
7. McFarland LV. Alternative treatments for Clostridium difficile disease: what really S..
.. works? Journal of Medical Microbiology (2005); 54: 101-11. * S.* * S *5* *
8. Fordtran JS. Colitis due to C!ostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Bay/or University Medical Center Proceedings (2006); 19(1): 3-12. S... S. S * S* * *.
Claims (23)
- CLAIMS1. An aqueous biocidal composition comprising: from 0.5 to 5% by weight of a chelating component comprising one or more chelating agents or salts thereof; ii. from 0.4 to 4% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and iii. from 0.6 to 5% by weight of a quaternary ammonium component comprising one or more trialkyl benzylammonium salts having at least one wherein the surfactant component and quaternary ammonium component are thfferent from each other.
- 2. The composition according to Claim 1, wherein the chelating component comprises or consists of one or more chelating agents selected from the group consisting of nitrilotriacetic acid, ethylenediaminetetraacetic acid, N-(hydroxyethyl)-ethylenediaminetriacetic acid, methyiglycinediacetic, hydroxyethyliminodiacetic acid, glutaric acid-N,N-diacetic acid, imiriodisuccinic acid or salts thereof.
- 3, The composition according to Claim I or Claim 2, wherein the chelating component comprises or consists of trisodium nitrilotriacetic acid.:
- 4. The composition according to any of the preceding claims, wherein the surfactant component comprises or consists of one or more surfactants selected from the group consisting of alkoxylated alcohols, alkyiphenols, amides, amines, esters, fatty acids or .. : glycerides; alkanolamides, amine oxides, esters, alkyl polyglucosides, betaines, glycinates, propionates, acetates and imidazolines. S...::: : 30
- 5. The composition according to any of the preceding claims, wherein the surfactant component comprises or consists of one or more alcohol ethoxylates having an alkyl group with a pendant chain of the structure -(OCH2CH2)mOH, wherein m is from 4 to 15.
- 6. The composition according to Claim 5, wherein the alkyl group is a C4-C20 alkyl.
- 7. The composition according to any of the preceding claims, wherein the quatemary ammonium component comprises or consists of one or more trialkyl benzylammonium salts having at least one C13-C16 alkyl substituent.
- 8. The composition according to Claim 7, wherein the quaternary ammoniurn component comprises or consists of one or more chloride salts of alkyldimethylbenzylammonium having a C12-C16 alkyl substituent.
- 9. The composition according to any of the preceding claims, wherein the chelating io component constitutes from I to 4.5% by weight of the composition, preferably from 2 to 3.5% by weight, most preferably from 2 to 2.5% by weight of the composition.
- 10. The composition according to any of the preceding claims, wherein the surfactant component constitutes from 0.7 to 3% by weight of the composition, preferably from 1 to 2% by weight, most preferably from 1.25 to 1.75% by weight of the composition.
- 11. The composition according to any one of the preceding claims, wherein the quatemary ammonium component constitutes from 1.5 to 4% by weight of the composition, preferably from 2 to 3.5% by weight, most preferably from 2.5 to 3% by weight of the composition.
- 12. A container comprising an aqueous biocidal composition according to any of Claims Ito 11. * . . * .*::::* 25
- 13. The container according to Claim 12, wherein the container comprises a spray nozzle. *.. * . SS
- 14. A wet wipe impregnated or coated with an aqueous biocidal composition according to any of Claims I to 11.::: : 30 *
- 15. A process for the preparation of an aqueous biocidal composition according to any of Claims 1 to 11 comprising forming a mixture comprising the chelating component, the surfactant component and the quaternary ammonium component.
- 16. The process according to Claim 15, wherein the chelating component, the surfactant component and the quaternary ammonium component are provided in the form of a concentrate comprising: from 5 to 20% by weight of a chelating component comprising one or more chelating agents or salts thereof; ii. from 2 to 15% by weight of a surfactant component comprising one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and mixtures thereof; and iii. from 5 to 20% by weight of a quatemary ammoniurn component comprising one or more trialkyl benzylammonium salts having at least one wherein the surfactant component and quatemary ammonium component are different from each other.
- 17. Use.of an aqueous biocidal composition according to any of Claims Ito 11 as an in vitro anti-microbial agent.
- 18. The use according to Claim 17, for killing, inhibiting or preventing the growth of bacteria, viruses, fungi and/or protozoa.
- 19. The use according to Claim 18, wherein the bacteria are selected from the group consisting of Mycobacteria spp., Staphylococcus spp., Clostridium spp. and Enterococcus spp.
- 20. The use according to Claim 19, wherein the bacteria are selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium terrae, Mycobacterium avium, 0*S Mycobacterium Bovis, methicillin-resistant Staphylococcus aureus, Clostridium difficile * 25 and vancomycin-resistant Enterococcus. ** S.:
- 21. The use according to any of Claims 18 to 20, wherein the bacteria are spore forming.: : 30
- 22. The use according to Claim 17 or Claim 18, for killing, inhibiting or preventing the * growth of spores of Clostridium diffidile.
- 23. The use according to Claim 18, wherein the virus is selected from the group consisting of norovirus, influenza, human immunodeficiency virus, Hepatitis B virus and Hepatitis C.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0817656A GB2463928A (en) | 2008-09-26 | 2008-09-26 | Composition |
| PCT/GB2009/002304 WO2010035008A2 (en) | 2008-09-26 | 2009-09-24 | Composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0817656A GB2463928A (en) | 2008-09-26 | 2008-09-26 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB0817656D0 GB0817656D0 (en) | 2008-11-05 |
| GB2463928A true GB2463928A (en) | 2010-04-07 |
Family
ID=40019612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0817656A Withdrawn GB2463928A (en) | 2008-09-26 | 2008-09-26 | Composition |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2463928A (en) |
| WO (1) | WO2010035008A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9578879B1 (en) | 2014-02-07 | 2017-02-28 | Gojo Industries, Inc. | Compositions and methods having improved efficacy against spores and other organisms |
| WO2015120216A1 (en) | 2014-02-07 | 2015-08-13 | Gojo Industries, Inc. | Compositions and methods with efficacy against spores and other organisms |
| CN110881463B (en) * | 2018-09-07 | 2021-12-03 | 中国科学院武汉植物园 | Method for preventing and treating fungal infection in haematococcus culture by using surfactant |
| GB202005499D0 (en) * | 2020-04-15 | 2020-05-27 | Pritchard Spray Ip Ltd | An aerosol dispenser |
| FR3135874A1 (en) * | 2022-05-31 | 2023-12-01 | Sodel | AQUEOUS DETERGENT AND/OR DISINFECTANT COMPOSITION |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2346375A (en) * | 1999-01-27 | 2000-08-09 | Reckitt & Colman Inc | Germicidal blooming type compositions containing biphenyl solvents |
| JP2004224703A (en) * | 2003-01-20 | 2004-08-12 | Teepol Diversey Kk | Sterilizing detergent composition for finger |
| WO2006086271A2 (en) * | 2005-02-07 | 2006-08-17 | Jacques Elfersy | Methods and compositions for biocidal treatments |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001246423A1 (en) * | 2000-03-09 | 2001-09-17 | Martin, Alexander | Bactericidal compositions comprising a quaternary ammonium salt |
| US20080260716A1 (en) * | 2004-07-09 | 2008-10-23 | Nanosonics Pty Limited | Method and Composition for High Level Disinfection Employing Quaternary Ammonium Compounds |
| US7754770B2 (en) * | 2005-06-27 | 2010-07-13 | Mason Chemical Company | Antimicrobial composition |
| GB0706739D0 (en) * | 2007-04-05 | 2007-05-16 | Alexander Ross Holdings Ltd | Composition |
| IL190181A (en) * | 2008-03-16 | 2015-08-31 | Altos Medical Llc | Cleaning, sanitising and sterilising preparations |
-
2008
- 2008-09-26 GB GB0817656A patent/GB2463928A/en not_active Withdrawn
-
2009
- 2009-09-24 WO PCT/GB2009/002304 patent/WO2010035008A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2346375A (en) * | 1999-01-27 | 2000-08-09 | Reckitt & Colman Inc | Germicidal blooming type compositions containing biphenyl solvents |
| JP2004224703A (en) * | 2003-01-20 | 2004-08-12 | Teepol Diversey Kk | Sterilizing detergent composition for finger |
| WO2006086271A2 (en) * | 2005-02-07 | 2006-08-17 | Jacques Elfersy | Methods and compositions for biocidal treatments |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010035008A2 (en) | 2010-04-01 |
| WO2010035008A3 (en) | 2011-07-07 |
| GB0817656D0 (en) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3136861B1 (en) | Composition containing peroxide and an antimicrobial agent and process of killing spores | |
| US8110538B2 (en) | Peracid/peroxide composition and use thereof as an anti-microbial and a photosensitizer | |
| ES2418079T3 (en) | Hydrogen peroxide disinfectant containing benzyl alcohol | |
| CN109414026A (en) | For the seamless permanent seal cooling composition for hard-surface cleaning and sterilization | |
| US20100222433A1 (en) | Composite Disinfectant Cleaner | |
| US20100055196A1 (en) | Sanitizing composition | |
| CA2884060C (en) | A prolonged disinfectant composition for non-biological surfaces comprising silver ion water and aloe vera | |
| EP0844827B1 (en) | Tuberculocidal synergistic disinfectant compositions and methods of disinfecting | |
| US10357034B2 (en) | Cleaning liquid | |
| JP7005492B2 (en) | Surface bactericidal agent with residual bactericidal properties | |
| RU2308292C2 (en) | Disinfecting agent | |
| US20240076582A1 (en) | Burstable sporicidal cleaning wipe system for c. difficile spores | |
| GB2463928A (en) | Composition | |
| JP2021008633A (en) | Antimicrobial composition | |
| BR112021008629A2 (en) | sanitizing or disinfecting composition, stable sanitizing or disinfecting composition, and ready-to-use sanitizing or disinfecting composition | |
| US11965145B2 (en) | Hard surface cleaner | |
| WO2008122773A2 (en) | Biocidal composition | |
| EP1713520B1 (en) | Cleaning composition | |
| WO2001037659A2 (en) | Biocide compositions | |
| JP2020523293A (en) | Surface germicide with residual germicidal properties | |
| RU2366175C1 (en) | Disinfectant | |
| US20220394979A1 (en) | Multipurpose disinfection solutions | |
| CZ36799U1 (en) | Disinfectant | |
| RU2194072C2 (en) | Disinfectant-detergent | |
| RU2778401C2 (en) | Surface-acting disinfectant with residual biocide property |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |